Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

LifeSci Advisors, LLC
Hans Vitzthum
(617) 430-7578
Hans@LifeSciAdvisors.com

Recent News

24Feb

CymaBay Therapeutics to Present at Upcoming Investor Conferences

10Feb

CymaBay Therapeutics to Present at the SVB Leerink 10th Annual Global Healthcare Conference

16Nov

CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver MeetingĀ® 2020

Upcoming Event

Mar 9 2021 7:00 am ET

H.C. Wainwright Global Life Sciences Conference

March 9, 2021 at 7:00 am ET

Q3 2020 Quarterly Results